Current multimodality management of medulloblastoma

Paulino, Arnold C.

doi:10.1067/mcn.2002.130267

Cited by 18 publications

(17 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of sex in predicting the outcomes of medulloblastoma patients is also controversial. There are a few series showing female patients having better prognosis both in children and adults [19]–[21], while others did not find sex influencing treatment outcomes significantly [22]. Our data revealed no independent prognostic significance according to age groups (<16 years vs. ≥16years) and sex in medulloblastoma patients.…”

Section: Discussioncontrasting

confidence: 77%

Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy

Zhang

Ren

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Medulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (CHT) is still limited. The authors performed a retrospective study of 173 medulloblastoma patients treated at two institutions from 2002 to 2011. Formalin-fixed paraffin embedded (FFPE) tissues were available in all the cases and sections were stained to classify histological and molecular subgroups. Univariate and multivariate analyses were used to investigate prognostic factors. Of 173 patients, there were 118 children and 55 adults, 112 males and 61 females. Estimated 5-year overall survival (OS) rates for all patients, children and adults were 52%, 48% and 63%, respectively. After multivariate analysis, postoperative primary radiation therapy (RT) and chemotherapy (CHT) were revealed as favorable prognostic factors influencing OS and EFS. Postoperative primary chemotherapy (CHT) was found significantly improving the survival of children (p<0.001) while it was not a significant prognostic factor for adult patients. Moreover, patients in WNT subtype had better OS (p = 0.028) than others (SHH and Non-SHH/WNT subtypes) given postoperative adjuvant therapies. Postoperative primary RT was found to be a strong prognostic factor influencing the survival in all histological and molecular subgroups (p<0.001). Postoperative primary CHT was found significantly to influence the survival of classic medulloblastoma (CMB) (OS p<0.001, EFS p<0.001), SHH subgroup (OS p = 0.020, EFS p = 0.049) and WNT subgroup (OS p = 0.003, EFS p = 0.016) but not in desmoplastic/nodular medulloblastoma (DMB) (OS p = 0.361, EFS p = 0.834) and Non-SHH/WNT subgroup (OS p = 0.127, EFS p = 0.055). Our study showed postoperative primary CHT significantly influence the survival of CMB, SHH subgroup and WNT subgroup but not in DMB and Non-SHH/WNT subgroup of MB.

show abstract

Section: Discussioncontrasting

confidence: 77%

Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy

Zhang

Ren

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…With regard to chemotherapy regimen, the current standard of care for EwingTs family tumors includes the use of ifosfamide and etoposide in addition to vincristine, doxorubicin, cyclophosphamide, and actinomycin D [60,65]. For cPNETs, combinations of vincristine and cisplatin with lomustine or with cyclophosphamide have been proven to be effective [63,66,67]. It is likely that future treatment protocols will continue to differ between pPNETs and cPNETs as targeting of tumor-specific oncogene expression may begin to play a role in treatment.…”

Section: Discussionmentioning

confidence: 99%

Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review

et al. 2006

View full text Add to dashboard Cite

“…Craniospinal irradiation (CSI) is used to treat patients with central nervous system malignancies that have a propensity for leptomeningeal metastasis, such as medulloblastoma (1,2). We have previously shown that three-dimensional (3D) conformal radiotherapy and linear accelerator-based intensity-modulated radiotherapy (IMRT) can be used for CSI (3,4) and, like other authors, have explored the use of helical TomoTherapy (HT) (TomoTherapy Inc., Madison, WI) for this purpose (5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 98%